Halozyme Therapeutics

HALO Nasdaq SEC CIK 1159036 LEI 529900242I3SV9AGM753
Follow Halozyme Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $493M +39.2% vs same quarter last year
Net income $247M +41% vs same quarter last year
EPS, diluted $2.01 +40.6% vs same quarter last year
Operating cash flow $258.3M +44.6% vs same quarter last year
Revenue by quarter
$298M
$264.9M
$325.7M
$354.3M
$451.8M
$376.7M
$481M
$493M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1B$1.5BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$1.4B$316.9M
FY24$1B$444.1M
FY23$829.3M$281.6M
FY22$660.1M$202.1M
FY21$443.3M$402.7M
FY20$267.6M$129.1M
FY19$196M−$72.2M
FY18$151.9M−$80.3M
FY17$316.6M$63M
FY16$146.7M−$103M
FY15$135.1M−$32.2M
FY14$75.3M−$68.4M
FY13$54.8M−$83.5M
FY12$42.3M−$53.6M
FY11$56.1M−$19.8M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200%−100%0%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2583.6%33.6%22.7%
FY2484.3%54.3%43.7%
FY2376.8%40.7%34%
FY2278.9%40.5%30.6%
FY2181.6%62.2%90.8%
FY2083.8%53.9%48.2%
FY1976.8%−34.5%−36.9%
FY1893.3%−45.7%−52.9%
FY1790.2%25.6%19.9%
FY1677.4%−56.7%−70.2%
FY1578.3%−20.3%−23.9%
FY1469.8%−83.7%−90.8%
FY1388.6%−146.8%−152.3%
FY1297.4%−126.7%−126.5%
FY1199.5%−35.4%−35.2%
Free cash flowOperating cash flow minus capital expenditure
−$200M$0$200M$400M$600M$800MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$644.6M
FY24$468.4M
FY23$373.3M
FY22$235.3M
FY21$298M
FY20$53M
FY19−$89.5M
FY18−$54.2M
FY17$132.7M
FY16−$53.5M
FY15−$39.4M
FY14−$48.9M
FY13−$51.6M
FY12−$65.7M
FY11−$35.1M
Returned to shareholdersDividends paid and shares bought back
$0$200M$400M$600MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$342.4M
FY24$250M
FY23$402.4M
FY22$200M
FY21$350.1M
FY20$150.1M
FY19$200M
FY18$0
FY17$0
FY16-
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Halozyme Therapeutics
  • Healthcare median
−200%−100%0%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearHalozyme TherapeuticsHealthcare median
FY2522.7%−30.6%
FY2443.7%−47%
FY2334%−58%
FY2230.6%−80.4%
FY2190.8%−71.9%
FY2048.2%−62.2%
FY19−36.9%−46.3%
FY18−52.9%−49.6%
FY1719.9%−45.9%
FY16−70.2%−36%
FY15−23.9%−38.4%
FY14−90.8%−35.5%
FY13−152.3%−37.1%
FY12−126.5%−29.1%
FY11−35.2%−27.9%